J.P. Morgan Day 4: Setting Goals For The Year Ahead

Updates from Viatris, Chi-Med, Novo Nordisk, Sangamo, Intercept, ImmunoGen

Daily round-up from the virtual J.P. Morgan Healthcare Conference: Viatris debuts; Chi-Med charts its own path; Novo takes another go at obesity; Sangamo moves forward with CAR-Treg; Intercept readies for resubmission; and ImmunoGen is relying on a safety advantage for its ADC. 

Viatris Inc. CEO Michael Goettler’s 14 January presentation was the company's first appearance at the J.P. Morgan Healthcare Conference since the merger of Mylan Pharmaceuticals Inc. and Pfizer Inc.'s Upjohn business, establishing the company, was completed in November.

He laid out a road map for what investors should expect from Viatris in two stages, the first, Horizon 1,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Cell & Gene Therapies

More from Advanced Technologies